APIXABAN

Post-LOE

apixaban

ANDAORALTABLET
Approved
Jul 2020
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

FXa. It does not require antithrombin III for antithrombotic activity. Apixaban inhibits free and clot-bound FXa, and prothrombinase activity. Apixaban has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, apixaban…

Clinical Trials (5)

NCT07015905Phase 3Recruiting

REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults

Started Jun 2025
2,000 enrolled
Venous Thromboembolism (VTE)
NCT06515730Phase 4Recruiting

Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction

Started Apr 2025
212 enrolled
Left Ventricular ThrombusAcute Myocardial Infarction
NCT06606275N/ACompleted

The Safety and Effectiveness of Warfarin Vs Apixaban in Patients with NVAF/ VTE and ESKD on Dialysis

Started Jan 2024
67 enrolled
End-Stage Kidney Disease (ESKD)Non-valvular Atrial Fibrillation (NVAF)Venous Thromboembolism (VTE)
NCT05757869Phase 3Active Not Recruiting

A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

Started Apr 2023
20,284 enrolled
Atrial Fibrillation
NCT05643573Phase 3Terminated

A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke

Started Dec 2022
14,830 enrolled
Prevention of Stroke or Systemic EmbolismAtrial Fibrillation